Cargando…
Recombinant allergy vaccines based on allergen-derived B cell epitopes
Immunoglobulin E (IgE)-associated allergy is the most common immunologically-mediated hypersensitivity disease. It affects more than 25% of the population. In IgE-sensitized subjects, allergen encounter can causes a variety of symptoms ranging from hayfever (allergic rhinoconjunctivitis) to asthma,...
Autores principales: | Valenta, Rudolf, Campana, Raffaela, Niederberger, Verena |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6390931/ https://www.ncbi.nlm.nih.gov/pubmed/28472641 http://dx.doi.org/10.1016/j.imlet.2017.04.015 |
Ejemplares similares
-
Vaccine development for allergen-specific immunotherapy based on recombinant allergens and synthetic allergen peptides: Lessons from the past and novel mechanisms of action for the future
por: Valenta, Rudolf, et al.
Publicado: (2016) -
Allergen Peptides, Recombinant Allergens and Hypoallergens for Allergen-Specific Immunotherapy
por: Marth, Katharina, et al.
Publicado: (2014) -
Allergen Extracts for In Vivo Diagnosis and Treatment of Allergy: Is There a Future?
por: Valenta, Rudolf, et al.
Publicado: (2018) -
Comparison of the immunogenicity of BM32, a recombinant hypoallergenic B cell epitope–based grass pollen allergy vaccine with allergen extract–based vaccines
por: Weber, Milena, et al.
Publicado: (2017) -
Poor association of allergen‐specific antibody, T‐ and B‐cell responses revealed with recombinant allergens and a CFSE dilution‐based assay
por: Eckl‐Dorna, J., et al.
Publicado: (2015)